3.40Open3.40Pre Close0 Volume200 Open Interest195.00Strike Price0.00Turnover107.87%IV17.82%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry3.40Extrinsic Value100Contract SizeAmericanOptions Type-0.1424Delta0.0052Gamma68.57Leverage Ratio-0.4511Theta-0.0100Rho-9.76Eff Leverage0.0896Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet